Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma.

Pharmacogenetics and genomics - 1 Jan 2012

Erčulj Nina, Kovač Viljem, Hmeljak Julija, Franko Alenka, Dodič-Fikfak Metoda, Dolžan Vita

Abstract excerpt

OBJECTIVE: Identification of biomarkers that could predict gemcitabine efficacy and toxicity is a key issue in the development of individualized therapy. The aim of our study was to evaluate the influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma (MM). METHODS: In total, 107 patients with MM, treated with gemcitabine-platinum chemotherapy, were genotyped for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Pharmacological
Share to Cytidine Deaminase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Disease-Free Survival

Share to Gemcitabine

Share to Mesothelioma

Share to Ribonucleoside Diphosphate Reductase

Share to Tumor Suppressor Proteins

Source

Identifiers

PMID: 22134350
DOI: 10.1097/FPC.0b013e32834e3572

Genes

RRM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma.PMID 22134350Read ↗

DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy.Semantic proximity Read ↗

Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.Semantic proximity Read ↗

The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesotheliomaSemantic proximity Read ↗

Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.Semantic proximity Read ↗

Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature‐based meta‐analysisSemantic proximity Read ↗

Predicting chemosensitivity to gemcitabine and cisplatin based on gene polymorphisms and mRNA expression in non-small-cell lung cancer cells.Semantic proximity Read ↗

Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine.Semantic proximity Read ↗

RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.Semantic proximity Read ↗

Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.Semantic proximity Read ↗

Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum.Semantic proximity Read ↗

An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients.Semantic proximity Read ↗

The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.